Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Emailed Dan

<< Previous

Bullboard Posts

Next >>

Comment by Marky1on Apr 05, 2021 7:54pm

265 Views

Post# 32939294

RE:Emailed Dan

Thank you for your efforts! I calculated your figures and I do feel that they are a bit high ...65M shares is 43% dilution while 70M is a whopping 54% dilution...You are probably somewhere in the ball park, I would say 64M or 42% dilution sounds about right...Remember, Dan and Johns holdings are diluted as well.
No matter how many shares there are...4B$ USD is where we will be bought out, in my humble opinion..

<< Previous

Bullboard Posts

Next >>

This battery metals stock is on a path to the global stage